Thymosin Alpha 1 Dosage: What Clinical Protocols and Vial Math Show

Thymosin alpha 1 is most commonly dosed at 1.6 mg given subcutaneously twice a week in the published clinical literature, a schedule used in hepatitis B and C trials and studied in sepsis, cancer care, and severe infections. Research and community protocols typically use 1.5 mg to 3 mg per injection, with larger amounts sometimes drawn from a 5 mg or 10 mg vial. No single FDA-approved dosage exists for general use in the United States, so any dosing plan should be set with a licensed clinician who knows your health history.

Why There Is No One-Size-Fits-All Dose

Thymosin alpha 1, also called thymalfasin, is a synthetic version of a peptide the thymus produces. It is sold as Zadaxin in roughly 30 countries and studied as an immune-modulating agent in the United States. The appropriate amount depends on the condition being targeted, body weight, route of administration, and the purity and concentration of the product.

US regulators have not approved thymosin alpha 1 for human use. That means dosing information comes from clinical trials, foreign product labels, and community self-experimentation rather than from an FDA-reviewed package insert.

Standard Clinical Dosing: 1.6 mg Twice Weekly

The most frequently cited clinical schedule is 1.6 mg subcutaneously twice per week, often for six months or longer. The main categories of reported medical protocols include:

• Chronic hepatitis B: 1.6 mg subcutaneously twice weekly for 6 months.
• Chronic hepatitis C: 1.6 mg twice weekly for 6 to 12 months, historically combined with interferon.
• Immune and oncology research: some studies use 0.9 mg per square meter of body surface area on a weekly or twice-weekly schedule.
• Sepsis and critical illness: more intensive regimens, such as 1.6 mg every 12 hours for several days followed by once-daily or twice-weekly maintenance.

Early hospital studies of thymosin alpha 1 covid dosage also used 1.6 mg subcutaneously, sometimes daily in critically ill patients and twice weekly in milder cases.

Thymosin Alpha 1 Dosage Chart: Reported Protocols Compared

The thymosin alpha 1 dosage chart below compares the most commonly reported protocols. It reflects published or widely shared schedules, not a universal recommendation.

Two conclusions stand out. Thymosin alpha 1 is not FDA-approved for human use in the United States. And 1.6 mg twice weekly is the dose that appears most often in the clinical record, which is why it is the reference point most people compare against.

Daily Versus Weekly Dosing

Most maintenance protocols are built around two or three injections per week rather than a daily shot. Daily dosing appears mainly in acute, closely monitored hospital settings.

If you are comparing thymosin alpha 1 dosage per day, remember that frequency changes total exposure quickly:

• 1.6 mg twice weekly equals 3.2 mg per week.
• 1.6 mg daily equals 11.2 mg per week.
• 3 mg twice weekly equals 6 mg per week.

A thymosin alpha 1 dosage calculator can convert vial strength into injection volume, but it cannot tell you whether a protocol is appropriate for you.

5 mg and 10 mg Vials: Reconstitution Math

Most research vials contain 5 mg or 10 mg of lyophilized powder, so doses are drawn by volume. The math depends on how much diluent you add:

• 5 mg vial plus 2 mL of bacteriostatic water equals 2.5 mg/mL. A 1.6 mg dose is 0.64 mL.
• 10 mg vial plus 2 mL equals 5 mg/mL. A 1.6 mg dose is 0.32 mL.
• 10 mg vial plus 1 mL equals 10 mg/mL. A 1.6 mg dose is 0.16 mL, which is difficult to measure accurately.

Using a 1 mL insulin syringe with half-unit or unit markings makes small volumes far easier to read. Adding more diluent lowers the concentration and improves measurement accuracy. Reconstituted peptide should be refrigerated and used within the stability window the supplier provides.

Injection Versus Nasal Spray

Subcutaneous injection is the route used in nearly all clinical research, and it produces the most predictable blood levels. Reported thymosin alpha 1 nasal spray dosage varies widely in community use, largely because absorption across nasal tissue is lower and not well characterized.

Oral capsules face a similar problem, since digestive enzymes break peptides down before they reach the bloodstream. Anyone comparing routes should treat injection data as the reference standard.

Safety and Side Effects

Clinical reports generally describe thymosin alpha 1 as well tolerated. The most common complaints are injection-site reactions, fatigue, and mild flu-like symptoms.

Because the peptide modulates immune activity, it deserves caution in people with autoimmune conditions, organ transplants, or active immunotherapy. Reviewing reported thymosin alpha 1 side effects with a clinician before starting is a sensible step.

Thymosin alpha 1 and thymosin beta 4 are often discussed together, but they are not interchangeable. Thymosin beta 4 dosage targets cell migration and tissue repair, while thymosin alpha 1 works through immune signaling pathways.

Questions to Ask Before You Dose

1. Is there published evidence for my specific condition at this dose?
2. What monitoring, such as bloodwork or symptom tracking, should accompany the protocol?
3. What is the plan if side effects appear?
4. Does the supplier provide a certificate of analysis for the batch?

Self-dosing with unapproved peptides carries real risk, including dosing errors, contamination, and unexpected immune reactions. A healthcare professional can help weigh the potential upside against those risks.